Table 3 Demographic and clinical data of healthy volunteers and patients with different alleles of GPR65 SNP rs8005161 used for further analysis
Healthy controls | rs8005161 CC | rs8005161 CT | rs8005161 TT | |
|---|---|---|---|---|
Number of patients | 8 | 8 | 9 | 9 |
Gender, females | 3 (37.5%) | 4 (50%) | 3 (33%) | 6 (66%) |
Age (median ± IQR) | 42 (37.5–47.5) | 46.7 (37.9–50.6) | 41.3 (33.9–51.4) | 43.1 (27.5–48.8) |
Diagnosis | ||||
UC/ CD (percent UC) | NA | 4/4 (50%) | 6/3 (66%) | 6/3 (66%) |
Disease severity | ||||
Harvey-Bradshaw Index (median, IQR) | NA | 6.0 (4.3–7.5) | 4 (3–4) | 1 (0.5–1) |
UC Severity Index (median, IQR) | NA | 4.0 (3.3–4.8) | 7.5 (3.5–10) | 0 (0–1.5) |
Medical history | ||||
Azathioprine / 6-Mercaptopurine | NA | 1/8 | 1/9 | 2/8 |
Methotrexate | NA | 0/8 | 1/9 | 0/8 |
Tacrolimus | NA | 1/8 | 0/9 | 0/8 |
Tumor necrosis factor inhibitor | NA | 4/8 | 3/9 | 1/8 |
Vedolizumab | NA | 4/8 | 5/9 | 1/8 |
Systemic steroids ≥10 mg/d | NA | 0/8 | 3/9 | 1/8 |
Oral mesalazine/ sulfasalazine | NA | 5/8 | 3/9 | 4/8 |